The American Heart Journal reported results of a clinical trial evaluating Amorcyte, Inc.'s lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction (AMI). Data demonstrated a significant relationship between cell dose and biologic effect...
No comments:
Post a Comment